Mostrar el registro sencillo del ítem
Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry
dc.contributor.author | Fachal Vilar, Laura | |
dc.contributor.author | Graña Suárez, Begoña | |
dc.contributor.author | Vega Gliemmo, Ana | |
dc.contributor.author | Santamariña Pena, Marta | |
dc.contributor.author | Blanco Pérez, Ana | |
dc.date.accessioned | 2017-06-07T07:09:31Z | |
dc.date.available | 2017-06-07T07:09:31Z | |
dc.date.issued | 2011 | |
dc.identifier.issn | 0167-6806 | |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/3246 | |
dc.description.abstract | Biallelic inactivation of ATM gene causes the rare autosomal recessive disorder Ataxia-telangiectasia (A-T). Female relatives of A-T patients have a two-fold higher risk of developing breast cancer (BC) compared with the general population. ATM mutation carrier identification is laborious and expensive, therefore, a more rapid and directed strategy for ATM mutation profiling is needed. We designed a case-control study to determine the prevalence of 32 known ATM mutations causing A-T in Spanish population in 323 BRCA1/BRCA2 negative hereditary breast cancer (HBC) cases and 625 matched Spanish controls. For the detection of the 32 ATM mutations we used the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry technique. We identified one patient carrier of the c.8264_8268delATAAG ATM mutation. This mutation was not found in the 625 controls. These results suggest a low frequency of these 32 A-T causing mutations in the HBC cases in our population. Further case-control studies analyzing the entire coding and flanking sequences of the ATM gene are warranted in Spanish BC patients to know its implication in BC predisposition. | |
dc.language.iso | eng | |
dc.title | Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry | |
dc.type | Artigo | es |
dc.authorsophos | Grana, B. | |
dc.authorsophos | Fachal, L. | |
dc.authorsophos | Darder, E. | |
dc.authorsophos | Balmana, J. | |
dc.authorsophos | Ramon, Y. Cajal T. | |
dc.authorsophos | Blanco, I. | |
dc.authorsophos | Torres, A. | |
dc.authorsophos | Lazaro, C. | |
dc.authorsophos | Diez, O. | |
dc.authorsophos | Alonso, C. | |
dc.authorsophos | Santamarina, M. | |
dc.authorsophos | Velasco, A. | |
dc.authorsophos | Teule, A. | |
dc.authorsophos | Lasa, A. | |
dc.authorsophos | Blanco, A. | |
dc.authorsophos | Izquierdo, A. | |
dc.authorsophos | Borras, J. | |
dc.authorsophos | Gutierrez-Enriquez, S. | |
dc.authorsophos | Vega, A. | |
dc.authorsophos | Brunet, J. | |
dc.identifier.doi | http://dx.doi.org/10.1007/s10549-011-1462-x | |
dc.identifier.pmid | 21445571 | |
dc.identifier.sophos | 9621 | |
dc.issue.number | 2 | |
dc.journal.title | BREAST CANCER RESEARCH AND TREATMENT | |
dc.organization | Consellería de Sanidade::Fundación pública Galega de Medicina Xenómica | |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ferrol::Xerencia da Área de Ferrol::Oncoloxía médica | |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago::IDIS.- Instituto de investigaciones sanitarias de Santiago | |
dc.page.initial | 573 | |
dc.page.final | 579 | |
dc.rights.accessRights | openAccess | |
dc.typesophos | Artículo Original | |
dc.volume.number | 128 |